Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACADNASDAQ:COLLNASDAQ:MRUSNASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$22.71-1.0%$18.84$13.40▼$25.23$3.80B0.641.96 million shs6.66 million shsCOLLCollegium Pharmaceutical$29.83+0.8%$28.57$23.23▼$42.29$958.44M0.63405,163 shs669,952 shsMRUSMerus$53.10+1.0%$47.82$33.19▼$62.98$3.68B1.04756,334 shs601,480 shsRNAAvidity Biosciences$29.310.0%$30.46$21.51▼$56.00$3.53B0.951.39 million shs1.51 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%+4.61%+3.32%+31.80%+48.43%COLLCollegium Pharmaceutical0.00%+2.23%+3.36%-2.39%-5.84%MRUSMerus0.00%-2.77%-3.70%+8.88%-3.17%RNAAvidity Biosciences0.00%-6.57%-4.15%-11.98%-24.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACADACADIA Pharmaceuticals3.6407 of 5 stars3.31.00.00.02.64.22.5COLLCollegium Pharmaceutical3.8817 of 5 stars3.41.00.03.02.70.81.9MRUSMerus3.2683 of 5 stars4.63.00.00.02.71.70.0RNAAvidity Biosciences2.3329 of 5 stars4.50.00.00.03.20.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.69Moderate Buy$26.7917.95% UpsideCOLLCollegium Pharmaceutical 2.75Moderate Buy$43.7546.66% UpsideMRUSMerus 3.14Buy$84.6459.39% UpsideRNAAvidity Biosciences 3.06Buy$66.56127.10% UpsideCurrent Analyst Ratings BreakdownLatest COLL, ACAD, MRUS, and RNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025RNAAvidity BiosciencesWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$55.006/11/2025RNAAvidity BiosciencesRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$65.006/10/2025RNAAvidity BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$70.00 ➝ $75.006/10/2025RNAAvidity BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $59.006/10/2025RNAAvidity BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $59.006/9/2025RNAAvidity BiosciencesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$48.00 ➝ $54.006/9/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$65.00 ➝ $75.006/6/2025ACADACADIA PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$26.00 ➝ $30.006/5/2025ACADACADIA PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/5/2025ACADACADIA PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Hold$18.00 ➝ $23.005/23/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M3.97$0.70 per share32.22$4.40 per share5.16COLLCollegium Pharmaceutical$631.45M1.52$12.33 per share2.42$7.10 per share4.20MRUSMerus$36.13M101.72N/AN/A$9.46 per share5.61RNAAvidity Biosciences$10.90M324.08N/AN/A$11.94 per share2.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3716.5829.884.8522.97%17.46%10.75%8/5/2025 (Estimated)COLLCollegium Pharmaceutical$69.19M$1.2224.454.96N/A6.61%99.08%15.14%8/6/2025 (Estimated)MRUSMerus-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)RNAAvidity Biosciences-$322.30M-$3.00N/AN/AN/A-4,136.00%-26.96%-24.57%8/8/2025 (Estimated)Latest COLL, ACAD, MRUS, and RNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/8/2025Q1 2025RNAAvidity Biosciences-$0.88-$0.90-$0.02-$0.90$2.63 million$1.60 million5/7/2025Q1 2025ACADACADIA Pharmaceuticals$0.10$0.11+$0.01$0.11$239.32 million$244.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/ACOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.882.80COLLCollegium Pharmaceutical3.301.081.01MRUSMerusN/A5.865.86RNAAvidity BiosciencesN/A16.9116.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%COLLCollegium PharmaceuticalN/AMRUSMerus96.14%RNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals28.30%COLLCollegium Pharmaceutical2.51%MRUSMerus4.57%RNAAvidity Biosciences3.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510167.36 million120.00 millionOptionableCOLLCollegium Pharmaceutical21032.13 million31.33 millionOptionableMRUSMerus3769.21 million66.05 millionOptionableRNAAvidity Biosciences190120.52 million115.90 millionOptionableCOLL, ACAD, MRUS, and RNA HeadlinesRecent News About These CompaniesAvidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027June 20 at 3:26 PM | investing.comAvidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $27,548.64 in StockJune 19, 2025 | insidertrades.comWolfe Research Begins Coverage on Avidity Biosciences (NASDAQ:RNA)June 19, 2025 | americanbankingnews.comAvidity Biosciences, Inc. (NASDAQ:RNA) Insider Kathleen P. Gallagher Sells 911 SharesJune 18, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Trading Up 4.1% - Here's WhyJune 17, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Coverage Initiated at Wolfe ResearchJune 17, 2025 | marketbeat.comAvidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potentialJune 16, 2025 | investing.comAvidity Biosciences (NASDAQ:RNA) Shares Down 3.5% - Here's What HappenedJune 16, 2025 | marketbeat.comAssenagon Asset Management S.A. Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)June 15, 2025 | marketbeat.comRhumbline Advisers Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)June 14, 2025 | marketbeat.comGAMMA Investing LLC Has $1.96 Million Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)June 14, 2025 | marketbeat.comLeerink Partnrs Analysts Decrease Earnings Estimates for RNAJune 14, 2025 | americanbankingnews.comW. Michael Flanagan Sells 20,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockJune 12, 2025 | marketbeat.comLeerink Partnrs Has Pessimistic View of RNA FY2026 EarningsJune 12, 2025 | marketbeat.comRaymond James Initiates Coverage of Avidity Biosciences (RNA) with Strong Buy RecommendationJune 12, 2025 | msn.comAvidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond JamesJune 11, 2025 | msn.comAvidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research CongressJune 11, 2025 | prnewswire.comCantor Fitzgerald Weighs in on RNA FY2026 EarningsJune 11, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at Raymond JamesJune 11, 2025 | marketbeat.com1RNA : The Analyst Verdict: Avidity Biosciences In The Eyes Of 12 ExpertsJune 10, 2025 | benzinga.comCitigroup Increases Avidity Biosciences (NASDAQ:RNA) Price Target to $75.00June 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingTesla Bulls and Bears Collide: What Investors Should KnowBy Sam Quirke | June 18, 2025View Tesla Bulls and Bears Collide: What Investors Should KnowCOLL, ACAD, MRUS, and RNA Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$22.71 -0.24 (-1.05%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$22.64 -0.07 (-0.33%) As of 06/20/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Collegium Pharmaceutical NASDAQ:COLL$29.83 +0.23 (+0.78%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$29.81 -0.02 (-0.07%) As of 06/20/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Merus NASDAQ:MRUS$53.10 +0.51 (+0.97%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$54.01 +0.91 (+1.72%) As of 06/20/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Avidity Biosciences NASDAQ:RNA$29.31 -0.01 (-0.03%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$29.56 +0.25 (+0.84%) As of 06/20/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
